FDA records linked by MedtechLedger identify Zimmer, Inc. as applicant on four orthopedic filings: three premarket approval actions under P060037 and one 510(k) premarket notification, K262955. The knee records concern a semi-constrained, metal/polymer mobile-bearing patellofemorotibial prosthesis under product code NJL, while the shoulder record concerns an uncemented metaphyseal humeral stem total anatomic shoulder prosthesis under product code PKC. The collection is an as-of snapshot of these filings, not a measure of company sales, total portfolio or safety performance. [1][2][3][4]
Knee system approval and its supplement history
P060037 was approved on December 10, 2007 for the NexGen LPS-Flex Mobile and LPS-Mobile Bearing Knee System, a Class III device under product code NJL. The approval statement describes cemented use and lists indications covering severe knee pain and disability from osteoarthritis, primary and secondary traumatic arthritis, avascular necrosis of the femoral condyle, and moderate valgus, varus or flexion deformities. The Summary of Safety and Effectiveness Data names Zimmer, Inc. at its Warsaw, Indiana address and records the same December 10, 2007 notice of approval. [4][6]
Two 30-Day Notice supplements followed in 2026, both decided OK30. S099, received September 15, 2026 and decided September 24, 2026, covers introduction of an Elma 3-Stage Parts Washer for femoral components at the Warsaw, Indiana facility. S100, received October 6, 2026 and decided October 16, 2026, covers expansion of ISO Class 7 packaging cleanroom space and corridor at the Warsaw West facility. Both are recorded under supplement reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. [1][3]
The FDA PMA page for P060037 notes that the device has supplements and that the device description, function or indications may have changed, directing readers to the supplements for current information. The page also links a Summary of Safety and Effectiveness, labeling, and a post-approval study report schedule. The physician labeling describes the LPS-Flex Mobile Bearing Knee and LPS-Mobile Bearing Knee as semi-constrained, non-linked, posterior-stabilized, rotating platform mobile bearing knee prostheses within the NexGen Complete Knee Solution LPS system. [5][10]
Shoulder system clearance
K262955 was cleared as substantially equivalent on September 24, 2026 for the OsseoFit Stemless Shoulder System, submitted and received August 24, 2026. The clearance letter identifies regulation number 21 CFR 888.3660, shoulder joint metal/polymer semi-constrained cemented prosthesis, Class II, product code PKC, and addresses the decision to Alexandria Irwin, Regulatory Affairs Sr Specialist, at the Warsaw, Indiana address. The FDA 510(k) database entry records the decision as Substantially Equivalent (SESE), review panel Orthopedic, type Special, not reviewed by a third party, with a summary available. [2][7][8]
The clearance letter lists predicate devices, with the primary predicate listed first, and includes a device description summary section referencing 21 CFR 807.92(a)(3). The openFDA device name for the clearance is prosthesis, total anatomic shoulder, uncemented metaphyseal humeral stem with no diaphyseal incursion, semi-constrained. The record does not establish commercial availability, pricing, customers or clinical results for this system. [2][8]
What the filing record does and does not establish
Across the full linked collection, decision counts are two OK30, one SESE and one APPR, spanning three PMA records and one 510(k) record. The smaller record sample of four entries carries the same counts, so the two denominators coincide here; neither should be read as a company-wide total. The earliest record is the 2007 original approval, and the three most recent decisions fall between September 24 and October 16, 2026. [1][2][3][4]
The records support a narrow set of facts: applicant identity, product names, product codes, regulation numbers where listed, supplement types and reasons, facility-related change descriptions, and decision dates and codes. They do not document headquarters, ownership, parent or brand relationships, website, manufacturing certifications, commercial availability or post-market safety performance. The FDA filing addresses appear in the records as applicant addresses and are not treated here as a verified headquarters. [1][2][3][4]



